Alijotas-Reig J, Marques-Soares J, Esteve-Valverde E, Anunciación-Llunell A, Andrada C, Ockova M, Hoxha A, Khamashta MA, Shoenfeld Y, Miró-Mur F.
Are the 2023 ACR/EULAR classification criteria a step forward in the management of antiphospholipid syndrome? A literature-based and clinical practice appraisal.
Autoimmun Rev. 2026 Jan;25(1):103956.
DOI: 10.1016/j.autrev.2025.103956. Epub 2025 Oct 29.
IF: 8.3
RESEARCH GROUPS
Systemic Diseases
69
Number of publications
59.42
%
% Q1
18.84
%
% D1
49.28
%
% Leadership
44.12
%
% Female Leadership
2.45
CROWN (2021-2025)
26.61
%
HCP10% (2021-2025)
56.52
%
% Open access
56.52
%
% International Collaboration
13
Highly cited papers / HCP 1% (2021-2025)
4
Publications in high-IF journals with high Altmetric scores
6
Number of Ongoing Projectes (total)
1
International ongoing projects
1
Number of New projects (total)
0
International new projects
41
Number of Active clinical Trials
8
Number of New Clinical Trials
1
Number of Theses
Our team has continued working on autoimmune diseases and autoinflammatory disorders. Studies focusing on the role of disturbances among immune cells, cytokines and autoantibodies and their relationship with recurrent pregnancy loss and inflammatory placental-related disorders are ongoing. Animal models and trophoblast organoids and the role played for aPL and chronic stress on poor obstetric outcomes have been included in this research. The relationship between myositis and systemic sclerosis and cancer, as well as different autoantibody profiles, were analysed. Recent reported autoimmune diseases in oncologic patients treated with check point inhibitors have also focused our interest. Gene-wide genetic and molecular signatures in systemic vasculitis, Sjögren syndrome and systemic sclerosis to find relationship with clinical subsets have been studied. We described a new risk haplotype for developing autoimmune/granulomatous disorders in women with breast implants.
CORE/MISSIONS
- Rare Diseases
PROGRAMS
- Robotic Surgery & Simulation
TEAM
Group Leader
Jaume Alijotas-Reig
Researchers
Jaume Alijotas-Reig, Segundo Buján-Rivas, Victoria Cardona Dahl, Enrique Esteve-Valverde, Mar Guilarte-Clavero, Alfredo Guillén-del Castillo, Moises Labrador Orrillo, Olga Luengo-Sanchez, Fernando Martinez-Vale, Jaume Mestres, Josep Pardos-Gea, Anna Sala-Conill, Albert Selva-O’Callaghan, Carmen Pilar Simeón-Aznar, Roser Solans-Laqué, Catalina Andrada, Ariadna Anunciación-Llunell, Aina Bruch Tarrega, Monika Ockova, Joan Rey Cano, Francesc Miró-Mur
SELECTED PUBLICATIONS
Solans-Laqué R, de Escalante-Yanguela B, Fonseca E, Fraile G, Martínez-Valle F, Caminal L, Monteagudo M, Pérez-Conesa M, Gracia-Tello B, Abdilla M, Prieto-González S, Martínez-Zapico A, de Miguel-Campo B, Mestre-Torres J; REVAS-Registry, from the Systemic Autoimmune Diseases Study Group (GEAS) of the Spanish Society of Internal Medicine (SEMI).
Identification of risk factors for permanent visual loss in patients with giant cell arteritis.
Eur J Intern Med. 2025 Sep;139:106372.
DOI: 10.1016/j.ejim.2025.06.001. Epub 2025 Jun 14.
IF: 6.1
Barreales-Rodríguez V, Guillen-Del-Castillo A, Berastegui C, López-Meseguer M, Monforte V, Saez-Gimenez B, Villar A, Ojanguren I, Codina-Clavaguera C, Fernández-Luque A, Sanz-Martínez MT, Viñas-Giménez L, Perurena-Prieto J, Triginer-Gil L, Alcalá-González L, Bravo C, Simeón Aznar CP
Change in Antinuclear Antibodies After Lung Transplantation in Patients with Systemic Sclerosis.
.J Clin Med. 2025 Dec 7;14(24):8673
DOI: 10.3390/jcm14248673.
IF: 2.9
Gil-Serrano J, Galvan-Blasco P, Pereira-Gonzalez J, Salvany-Pijuan A, Gonzalez Di-Paolo M, Guilarte M, Luengo O, Sala-Cunill A, Cardona V, Labrador-Horrillo M.J
Adrenaline: A Lifeline for Rapid Drug Desensitization in Hypersensitive Patients.
Investig Allergol Clin Immunol. 2026 Apr 14;36(2):113-120
DOI: 10.18176/jiaci.1075. Epub 2025 Apr 25
IF: 5.0
Anunciación-Llunell A, Marques-Soares J, Ockova M, Pozuelo N, Esteve-Valverde E, Andrada C, Alijotas-Reig J, Miró-Mur FA.
The absence of standardization in antiphospholipid antibody testing may favor the use of 99th percentile cutoffs in antiphospholipid syndrome classification.
Res Pract Thromb Haemost. 2025 Jul 7;9(5):102967
DOI: 10.1016/j.rpth.2025.102967. eCollection 2025 Jul.
IF: 3.5
SELECTED PROJECTS
Statin Intervention for Severe Early-Onset Placental Insufficiency: A Randomized Controlled Trial Assessing daily Administration as a Treatment Strategy (STATIN-PRE trial) (Project: [166/C/2024])
Principal Investigator: Elisa Llurba and jaume Alijotas-Reig
Agency: La Marató
Funding: 396,000 €
Period: 2024-2027
Antiphospholipid antibody-induced trained immunity in monocytes as a cause of obstetric morbidity in antiphospholipid syndrome (PI:24/01302)
Principal Investigator: Francesc Miró-Mur and IP senior: Jaume Alijotas-Reig
Agency: FIS. ISCIII
Funding: 105,000 €
Period: 2024-2027
Functional characterization of the genetic regions associated to systemic sclerosis (FunES). (FISS PI22/01804)
Principal Investigator: Alfredo Guillen Del Castillo
Agency: FISS ASCIII
Funding: 75,020 €
Period: 2023-2025
Identification of cellular and molecular biomarkers in idiopathic and hereditary angioedema (HAE) (PI20 01061)
Principal Investigator: Mar Guilarte Clavero
Agency: AES. Proyectos de Investigación en Salud
Funding: 84,700 €
Period: 2022-2025
Unveiling new autoantibodies in Sjögren Syndrome (PI24/01620)
Principal Investigator: Jaume Mestres
Agency: ISCIII
Funding: 65,000 €
Period: 2025-2027
PATENTS
A method for detecting susceptibility to develop adverse said effects related to bioimplants
Priority Number: EP2011/056393
Priority Date: 21/04/2011
Applicants: VHIR (100%)
DISSEMINATION ACTIVITIES
Flow citometry course: theory and applications
Place: VHIR Collserola building
Date: 28/10/2025 - 31/10/2025
Brief: Why performed a seminar of what implement a new pannel for cytometry
